
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7840604/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Availability of technology for managing cancer patients in the Southeast European (SEE) region. Clinical and Translational Radiation Oncology, 2022, 34, 57-66.	1.7	1
2	South East European International Institute for Sustainable Technologies (SEEIIST). Frontiers in Physics, 2021, 8, .	2.1	6
3	Surveying the Challenges to Improve Linear Accelerator-based Radiation Therapy in Africa: a Unique Collaborative Platform of All 28 African Countries Offering Such Treatment. Clinical Oncology, 2021, 33, e521-e529.	1.4	15
4	Patients With Cancer in the Countries of South-East Europe (the Balkans) Region and Prospective of the Particle Therapy Center: South-East European International Institute for Sustainable Technologies (SEEIIST). Advances in Radiation Oncology, 2021, 6, 100772.	1.2	4
5	Arbitrarily large tomography with iterative algorithms on multiple GPUs using the TIGRE toolbox. Journal of Parallel and Distributed Computing, 2020, 146, 52-63.	4.1	19
6	Achieving flexible competence: bridging the investment dichotomy between infectious diseases and cancer. BMJ Global Health, 2020, 5, e003252.	4.7	4
7	Overcoming Challenges in Providing Radiation Therapy to Patients With Cancer in Nigeria and Experience in the National Hospital Abuja, Nigeria. JCO Global Oncology, 2020, 6, 1232-1236.	1.8	8
8	Abstract D066: A prospective study on chemotherapy-induced anemia using serial hemoglobin measurement in cancer patients undergoing treatment at National Hospital Abuja, Nigeria. , 2020, , .		0
9	Capturing Acquired Wisdom, Enabling Healthful Aging, and Building Multinational Partnerships Through Senior Clobal Health Mentorship. Clobal Health, Science and Practice, 2020, 8, 626-637.	1.7	2
10	Developing Innovative, Robust and Affordable Medical Linear Accelerators for Challenging Environments. Clinical Oncology, 2019, 31, 352-355.	1.4	11
11	Overview of research and therapy facilities for radiobiological experimental work in particle therapy. Report from the European Particle Therapy Network radiobiology group. Radiotherapy and Oncology, 2018, 128, 14-18.	0.6	21
12	Accurate, Precision Radiation Medicine: A Meta-Strategy for Impacting Cancer Care, Global Health, and Nuclear Policy and Mitigating Radiation Injury From Necessary Medical Use, Space Exploration, and Potential Terrorism. International Journal of Radiation Oncology Biology Physics, 2018, 101, 250-253.	0.8	13
13	ENLIGHT: European network for Light ion hadron therapy. Radiotherapy and Oncology, 2018, 128, 76-82.	0.6	23
14	Union of light ion therapy centers in Europe (ULICE EC FP7) – Objectives and achievements of joint research activities. Radiotherapy and Oncology, 2018, 128, 83-100.	0.6	6
15	Role of Multidisciplinary Collaborative Network for Advancing Cancer Therapy. , 2018, , 107-113.		Ο
16	A general method for motion compensation in x-ray computed tomography. Physics in Medicine and Biology, 2017, 62, 6532-6549.	3.0	10
17	Effective Global Cancer Care Requires Radiation Therapy: Defining a Path From No Radiotherapy to Radiotherapy of High Quality Globally. Journal of Global Oncology, 2017, 3, 16s-16s.	0.5	0
18	Medical Applications at CERN and the ENLIGHT Network. Frontiers in Oncology, 2016, 6, 9.	2.8	6

#	Article	IF	CITATIONS
19	Monte Carlo Calculations Supporting Patient Plan Verification in Proton Therapy. Frontiers in Oncology, 2016, 6, 62.	2.8	7
20	TIGRE: a MATLAB-GPU toolbox for CBCT image reconstruction. Biomedical Physics and Engineering Express, 2016, 2, 055010.	1.2	170
21	An analytical model of tumour response to radiotherapy to investigate biological parameters of chordoma treated by X-rays, protons and carbon ions. Physica Medica, 2016, 32, 254.	0.7	Ο
22	Introduction to the EC's Marie Curie Initial Training Network Project: The European Training Network in Digital Medical Imaging for Radiotherapy (ENTERVISION). Frontiers in Oncology, 2015, 5, 265.	2.8	2
23	ENLIGHT and LEIR biomedical facility. Physica Medica, 2014, 30, 544-550.	0.7	5
24	Data-driven Markov models and their application in the evaluation of adverse events in radiotherapy. Journal of Radiation Research, 2013, 54, i49-i55.	1.6	6
25	A Monte Carlo-based treatment-planning tool for ion beam therapy. Journal of Radiation Research, 2013, 54, i77-i81.	1.6	40
26	Feasibility study for a biomedical experimental facility based on LEIR at CERN. Journal of Radiation Research, 2013, 54, i162-i167.	1.6	6
27	A possible biomedical facility at the European Organization for Nuclear Research (CERN). British Journal of Radiology, 2013, 86, 20120660.	2.2	15
28	Hadron therapy information sharing prototype. Journal of Radiation Research, 2013, 54, i56-i60.	1.6	1
29	Introduction to the EC's Marie Curie Initial Training Network (MC-ITN) project: Particle Training Network for European Radiotherapy (PARTNER). Journal of Radiation Research, 2013, 54, i1-i5.	1.6	6
30	Investigating the robustness of ion beam therapy treatment plans to uncertainties in biological treatment parameters. Physics in Medicine and Biology, 2012, 57, 7983-8004.	3.0	43
31	ENLIGHT. Health Physics, 2012, 103, 674-680.	0.5	6
32	A community call for a dedicated radiobiological research facility to support particle beam cancer therapy. Radiotherapy and Oncology, 2012, 105, 1-3.	0.6	28
33	Simulations of microdosimetric quantities with the Monte Carlo code FLUKA for carbon ions at therapeutic energies. International Journal of Radiation Biology, 2012, 88, 176-182.	1.8	14
34	Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: the PANDORA-01 trial. BMC Cancer, 2012, 12, 137.	2.6	46
35	Connection of European particle therapy centers and generation of a common particle database system within the European ULICE-framework. Radiation Oncology, 2012, 7, 115.	2.7	11
36	FLUKA simulations of the response of tissue-equivalent proportional counters to ion beams for applications in hadron therapy and space. Physics in Medicine and Biology, 2011, 56, 6545-6561.	3.0	19

#	Article	IF	CITATIONS
37	ENLIGHT and other EU-funded projects in hadron therapy. British Journal of Radiology, 2010, 83, 811-813.	2.2	14
38	Benchmarking nuclear models of FLUKA and GEANT4 for carbon ion therapy. Physics in Medicine and Biology, 2010, 55, 5833-5847.	3.0	142
39	Development of Hadron Therapy for Cancer Treatment in Europe. AlP Conference Proceedings, 2008, , .	0.4	1
40	Development of a new photo-detector readout technique for PET and CT imaging. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2007, 571, 329-332.	1.6	5
41	Status of hadron therapy in Europe and the role of ENLIGHT. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2007, 571, 191-194.	1.6	17
42	MODULATION OF PROTO-ONCOGENE EXPRESSION BY POLYCHLORINATED BIPHENYLS IN 3T3-L1 CELL LINE. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1998, 55, 121-131.	2.3	10
43	Isolation and characterization of RAD51C, a new human member of the RAD51 family of related genes. Nucleic Acids Research, 1998, 26, 1179-1184.	14.5	152
44	Suppression of apoptosis by overexpression of Bcl-2 or Bcl-xL promotes survival and mutagenesis after oxidative damage. Biochimie, 1997, 79, 613-617.	2.6	52
45	Metabolism Of Benzo[<i>a</i>]Pyrene in Fish Hepatocytes Cultured on Microplates. Polycyclic Aromatic Compounds, 1996, 11, 91-98.	2.6	8
46	Synthesis and properties of oligonucleotides containing the mutagenic base O4-benzylthymidine. Bioorganic and Medicinal Chemistry, 1995, 3, 101-108.	3.0	9
47	All four known cyclic adducts formed in DNA by the vinyl chloride metabolite chloroacetaldehyde are released by a human DNA glycosylase Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 1024-1028.	7.1	148
48	Synthesis of a 25 base oligonucleotide containing a styrene oxide modification at the O6 position of 2'-deoxyguanosine at a defined site and incorporation studies of the similarly modified 2'-deoxy guanosine-5' -triphosphate. Carcinogenesis, 1994, 15, 1371-1375.	2.8	1
49	1,N6-Ethenoadenine Is Preferred over 3-Methyladenine as Substrate by a Cloned Human N-Methylpurine-DNA Glycosylase (3-Methyladenine-DNA Glycosylase). Biochemistry, 1994, 33, 1624-1628.	2.5	87
50	Evidence from in vitro replication that O6-methylguanine can adopt multiple conformations Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 3983-3987.	7.1	19
51	Both O4-methylthymine and O4-ethylthymine preferentially form alkyl T.G pairs that do not block in vitro replication in a defined sequence. Carcinogenesis, 1993, 14, 1915-1919.	2.8	29
52	Both purified human 1,N6-ethenoadenine-binding protein and purified human 3-methyladenine-DNA glycosylase act on 1,N6-ethenoadenine and 3-methyladenine Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 9386-9390.	7.1	106
53	Kinetics of extension of O6-methylguanine paired with cytosine or thymine in defined oligonucleotide sequences. Biochemistry, 1991, 30, 11595-11599.	2.5	73
54	The vinyl chloride DNA derivative N2,3-ethenoguanine produces GA transitions in Escherichia coli Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 9974-9978.	7.1	130

#	Article	IF	CITATIONS
55	Comparative mutagenesis of O6-methylguanine and O4-methylthymine in Escherichia coli. Biochemistry, 1991, 30, 7027-7033.	2.5	64
56	Human cells contain protein specifically binding to a single 1,N6-ethenoadenine in a DNA fragment Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 6839-6842.	7.1	38
57	Comparative efficiency of forming m4T.cntdot.G versus m4T.cntdot.A base pairs at a unique site by use of Escherichia coli DNA polymerase I (Klenow fragment) and Drosophila melanogaster polymerase .alphaprimase complex. Biochemistry, 1990, 29, 4698-4703.	2.5	42
58	Site-directed mutagenesis for quantitation of base-base interactions at defined sites. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1990, 233, 45-51.	1.0	45
59	Effect of 3' flanking neighbors on kinetics of pairing of dCTP or dTTP opposite O6-methylguanine in a defined primed oligonucleotide when Escherichia coli DNA polymerase I is used Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 8271-8274.	7.1	110
60	CANCER IN THE COUNTRIES OF THE SEE (BALKANS) REGION AND THE FUTURE PARTICLE THERAPY CENTER $\hat{a} \in \hat{s}$ SEEIIST. , 0, , .		0